Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 12 |
Bispecific antibody | 7 |
Small molecule drug | 2 |
Antibody drug conjugate (ADC) | 2 |
Biological products | 1 |
Target |
Mechanism IL-12p40 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date15 Apr 2025 |
Target |
Mechanism PCSK9 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date26 Sep 2024 |
Target |
Mechanism PD-1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date21 May 2024 |
Start Date22 Jul 2025 |
Sponsor / Collaborator |
Start Date01 Jul 2025 |
Sponsor / Collaborator |
Start Date25 Jun 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Cadonilimab ( CTLA4 x PD-1 ) | Recurrent Cervical Cancer More | Approved |
Ivonescimab ( PD-1 x VEGF-A ) | EGFR positive Non-squamous non-small cell lung cancer More | Approved |
Penpulimab ( PD-1 ) | Nasopharyngeal Carcinoma More | Approved |
Quavonlimab ( CTLA4 ) | Renal Cell Carcinoma More | Phase 3 |
Ligufalimab ( CD47 ) | High Risk Myelodysplastic Syndrome More | Phase 2 |